This combination regimen could down-regulate the expression levels of RAD51 and BRCA as HR-related genes besides displaying a synergistic enhancement of cytotoxicity in ovarian cancer cell lines with functional and non-functional DNA repair systems. This evidence concerns the gene RAD51 and ovarian carcinoma.